as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹192.57
Change
+2.45 (1.29%)
Open
₹190.65
Prev. Close
₹190.12
Day High
₹194.26
Day Low
₹188.1
Volume Analysis
Traded
606,222
Delivered
210,313
Delivery %
34.69%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (279.0%)
- •Strong operating margin (85.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year revenue growth (98.8%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹201.34 | ₹197.8 | ₹195.18 | ₹191.64 | ₹189.02 | ₹185.48 | ₹182.86 |
| Fibonacci | ₹197.8 | ₹195.45 | ₹193.99 | ₹191.64 | ₹189.29 | ₹187.83 | ₹185.48 |
| Camarilla | ₹194.26 | ₹193.7 | ₹193.13 | ₹191.64 | ₹192.01 | ₹191.44 | ₹190.88 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+42.61%
1 Week
-9.31%
1 Month
+7.42%
3 Months
-2.1%
6 Months
-8.2%
1 Year
+39.48%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹218.66
Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
110.02%
Net margin 84.68% × asset turnover 1.12x × equity multiplier 1.16x
Company Overview
Sector
Healthcare
Market Cap
₹6,680 Cr
P/E (TTM)
4.05
ROE
279.0%
Book Value
₹44.4
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Sun Pharma Adv.res.co.ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (23/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (279.0%); strong operating margin (85.0%). Strong 3-year revenue growth (98.8%).
TopFund Score — Fundamentals Quality
66/100 — GoodData confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- −Stock is trading at 4.63 times its book value
- −Working capital days have increased from -768 days to 215 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
NSE and BSE grant reclassification approval for Krishna, Sudhir and Raksha Valia from promoter group to public.
SPARC confirms compliance and denies any undisclosed information behind volume increase.
Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on November 11, 2026, with reference to Movement in Volume.
Newspaper Advertisement for Publication of Financial Results
Monitoring agency report for Q2 FY27 shows no deviation in warrant proceeds; 150 Cr utilized.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 | 30 |
| Expenses + | 113 | 116 | 122 | 110 | 116 | 89 | 80 | 62 | 74 | 65 | 80 | 74 | 76 |
| Operating Profit | -91 | -103 | -106 | -93 | -103 | -74 | -53 | -52 | -66 | -57 | 1,773 | -34 | -46 |
| OPM % | -432.0% | -740.0% | -639.0% | -555.0% | -800.0% | -494.0% | -196.0% | -540.0% | -836.0% | -670.0% | 96.0% | -85.0% | -152.0% |
| Other Income + | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 | 0 | -12 | 2 | 24 | 24 |
| Interest | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 | 12 | 8 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Profit before tax | -86 | -100 | -105 | -96 | -107 | -79 | -61 | -52 | -76 | -80 | 1,761 | -21 | -24 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% |
| Net Profit + | -86 | -100 | -106 | -96 | -107 | -80 | -60 | -52 | -76 | -80 | 1,761 | -21 | -24 |
| EPS in Rs | -3 | -3 | -3 | -3 | -3 | -2 | -2 | -2 | -2 | -2 | 54 | -1 | -1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | -65 | -30 | -39 | 8 | 64 | -43 | -39 | -43 | 6,716 | 314 | 282 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales + | 239 | 76 | 72 | 1,879 | 1,932 |
| Expenses + | 453 | 478 | 395 | 280 | 295 |
| Operating Profit | -214 | -402 | -323 | 1,599 | 1,637 |
| OPM % | -90.0% | -532.0% | -450.0% | 85.0% | 85.0% |
| Other Income + | 11 | 29 | 2 | -2 | 37 |
| Interest | 8 | 2 | 9 | 34 | 29 |
| Depreciation | 12 | 13 | 12 | 10 | 9 |
| Profit before tax | -223 | -387 | -343 | 1,553 | 1,636 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Net Profit + | -223 | -387 | -343 | 1,553 | 1,636 |
| EPS in Rs | -7 | -12 | -11 | 48 | 50 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | -68 | -5 | 2,518 | 3,141 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Reserves | 480 | 93 | -249 | 1,306 | 1,410 |
| Borrowings + | 16 | 61 | 269 | 559 | 2 |
| Other Liabilities + | 302 | 328 | 284 | 273 | 229 |
| Total Liabilities | 830 | 515 | 336 | 2,171 | 1,674 |
| Fixed Assets + | 106 | 108 | 99 | 85 | 153 |
| CWIP | 27 | 44 | 54 | 72 | 3 |
| Investments | 291 | 2 | 0 | 0 | 239 |
| Other Assets + | 406 | 362 | 183 | 2,014 | 1,279 |
| Total Assets | 830 | 515 | 336 | 2,171 | 1,674 |
| Equity Capital | 32 | 32 | 32 | 32 | 32 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -69 | -429 | -360 | -239 |
| Cash from Investing Activity + | -548 | 392 | 158 | -23 |
| Cash from Financing Activity + | 617 | 42 | 199 | 261 |
| Net Cash Flow | -1 | 5 | -3 | -1 |
| Free Cash Flow | -84 | -455 | -370 | -262 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 35 | 106 | 114 | -17 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 30.36% | 30.41% | 31.51% | 31.96% | 31.47% | 31.76% | 31.88% | 31.52% | 31.51% | 31.41% | 30.34% | 30.48% |
| Promoters | 65.68% | 65.68% | 65.68% | 65.68% | 65.68% | 65.68% | 65.67% | 65.67% | 65.67% | 65.67% | 65.68% | 65.68% |
| FII | 3.3% | 3.24% | 2.64% | 2.15% | 2.23% | 1.45% | 1.47% | 1.76% | 2.04% | 2.04% | 3.9% | 3.74% |
| DII | 0.67% | 0.67% | 0.17% | 0.21% | 0.64% | 1.13% | 0.97% | 1.05% | 0.78% | 0.88% | 0.09% | 0.11% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sun Pharma Adv.res.co.ltd (this stock) | 6,680 | 4.05 | 4.64 | 279.0% |
| Nephrocare Health Serv L | 6,500 | 50.8 | 5.46 | 8.83% |
| Bliss Gvs Pharma Ltd | 7,075 | 43.5 | 5.5 | 11.8% |
| Kovai Medical Center & Ho | 7,108 | 123.0 | 24.58 | 22.2% |
| Fdc Limited | 6,177 | 18.8 | 2.31 | 11.5% |
| Innova Captab Limited | 5,938 | 35.6 | 5.09 | 13.7% |
| Sanofi India Limited | 7,603 | 17.2 | 8.83 | 47.1% |
Which Mutual Funds Hold Sun Pharma Adv.res.co.ltd?
Frequently Asked Questions about Sun Pharma Adv.res.co.ltd
Sun Pharma Adv.res.co.ltd (SPARC) closed at ₹192.57 on NSE on 19 November 2026, up 2.45 (1.29%) from the previous close.
Sun Pharma Adv.res.co.ltd trades on the NSE (National Stock Exchange of India) under the symbol SPARC.
Sun Pharma Adv.res.co.ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 4.05.
Sun Pharma Adv.res.co.ltd has a dividend yield of 0.0%.
Sun Pharma Adv.res.co.ltd's 52-week high is ₹289.0 and its 52-week low is ₹108.0.
Sun Pharma Adv.res.co.ltd has a market capitalisation of ₹6,680 crore.
Sun Pharma Adv.res.co.ltd has a TopFund Quality Score of 66/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sun Pharma Adv.res.co.ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.